Arcturus Therapeutics (ARCT) to Release Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) is anticipated to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.07) per share and revenue of $3.1080 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Friday, May 8th. The biotechnology company reported ($0.95) EPS for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. The business had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $6.30 million. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. On average, analysts expect Arcturus Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arcturus Therapeutics Trading Up 3.7%

ARCT stock opened at $6.22 on Wednesday. The business’s 50-day moving average price is $6.85 and its two-hundred day moving average price is $7.40. The firm has a market cap of $176.77 million, a PE ratio of -2.21 and a beta of 2.39. Arcturus Therapeutics has a 1-year low of $5.50 and a 1-year high of $24.17.

Institutional Trading of Arcturus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. ARK Investment Management LLC boosted its position in shares of Arcturus Therapeutics by 39.4% during the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock worth $16,006,000 after buying an additional 738,378 shares during the period. Vanguard Group Inc. boosted its position in Arcturus Therapeutics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,885,605 shares of the biotechnology company’s stock worth $34,752,000 after acquiring an additional 75,440 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Arcturus Therapeutics by 112.0% during the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock worth $11,428,000 after acquiring an additional 327,626 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Arcturus Therapeutics by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 618,134 shares of the biotechnology company’s stock valued at $3,790,000 after purchasing an additional 6,311 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Arcturus Therapeutics by 1,371.4% during the third quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company’s stock worth $10,177,000 after purchasing an additional 514,652 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Analysts Set New Price Targets

ARCT has been the subject of several recent analyst reports. Wall Street Zen downgraded Arcturus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Arcturus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $24.25.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.